Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial.

Shahin MeratElham JafariAmir Reza RadmardMasoud KhoshniaMaryam SharafkhahAlireza Nateghi BaygiTom MarshallAbolfazl Shiravi KhuzaniKar-Keung Cheng Hossein Poustchi Reza Malekzadeh

Published in: European heart journal (2022)

Among patients consenting to receive fixed-dose combination therapy, polypill is safe and effective for the prevention of MCVE, even among participants with fatty liver and increased liver enzymes.

Keyphrases

combination therapy
cardiovascular disease
clinical trial
study protocol
randomized controlled trial
phase ii
metabolic syndrome
coronary artery disease
fatty acid
liver injury